Press Releases Oragenics, Inc.

Equities

Market Closed - Nyse Other stock markets 01:40:00 16/05/2024 am IST			5-day change	1st Jan Change
1.638 ^USD	-0.73%		+35.37%	-70.89%

07/05	Oragenics, Inc. Announces Partnership with Avance Clinical to Conduct Phase II Clinical Trial in Australia	CI
12/04	North American Morning Briefing : Big Banks Kick -2-	DJ

Oragenics: Q1 Earnings Snapshot	15/05	AQ
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia	07/05	AQ
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	20/04	BU
Oragenics, Inc. Files 10K and Provides Company Update	01/04	BU
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18/03	BU
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03	BU
Oragenics Announces Closing of Public Offering	04/03	AQ
Oragenics Announces Closing of Public Offering	02/03	BU
Oragenics Announces Pricing of Public Offering	28/02	BU
Oragenics Announces Proposed Public Offering	28/02	BU
Oragenics, Inc. Announces Leadership Transition	13/02	BU
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement	07/02	BU
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion	05/02	BU
Oragenics Announces Termination of At-The-Market Offering Program	24/01	BU
Oragenics Completes Acquisition of Odyssey Health's Neurological Assets	02/01	AQ
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets	02/01	BU
Oragenics: Q3 Earnings Snapshot	10/11	AQ
Oragenics Issues Update to Shareholders	02/11	BU
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors	18/23/18	BU
OTC Stocks On The Move (SWISF, EPAZ, ODYY, PNXLF)	06/23/06	AQ

No results for this search